Treatment of latent tuberculosis with rifampkin is associated with higher completion rates

Nadig, V.
February 2007
Thorax;Feb2007, Vol. 62 Issue 2, p167
Academic Journal
The article presents a study which investigates the effectiveness of rifampicin as treatment for latent tuberculosis infection (LTBI) in the U.S. Medical records of 2,255 patients who received the treatment between January 1999 and January 2004 were reviewed. One group received isoniazid for 9 months and the other group received rifampicin for 4 four months. The results indicated higher completion rates to LTBI treatment with rifampicin compared with isoniazid.


Related Articles

  • NEWS ROUNDUP. Dziedzic, Jessica // Pulmonary Reviews;Jan2007, Vol. 12 Issue 1, p4 

    The article presents several studies concerning pulmonary disorders. Patients prescribed four months of rifampin treatment for latent tuberculosis infection (LTBI) may be more likely to complete therapy than those prescribed nine months of isoniazid. The use of tresprostinil to treat pulmonary...

  • Nonsteroidal Antiinflammatory Drugs for Adjunctive Tuberculosis Treatment. Ivanyi, Juraj; Zumla, Alimuddin // Journal of Infectious Diseases;Jul2013, Vol. 208 Issue 2, p185 

    The article offers information on the role and efficacy of nonsteroidal anti-inflammatory drugs for adjunctive tuberculosis treatment. It adds that despite of the availability of effective treatment since the 1970 tuberculosis continues to cause 1.4 million deaths annually. As mentioned, the...

  • Multidrug-resistant TB more widespread.  // Materials Management in Health Care;Feb2007, Vol. 16 Issue 2, p6 

    The article reports on the proliferation of multidrug-resistant tuberculosis (TB) cases worldwide. It could be noted that this disease can hold treatment with potent anti-TB drugs isoniazid and rifampicin. The World Health Organization researchers found out that in 2004, there were more than...

  • Safety of 3 Different Reintroduction Regimens of Antituberculosis Drugs after Development of Antituberculosis Treatment-Induced Hepatotoxicity. Sharma, Surendra K.; Singla, Rohit; Sarda, Pawan; Mohan, Alladi; Makharia, Govind; Jayaswal, Arvind; Sreenivas, Vishnubhatla; Singh, Sarman // Clinical Infectious Diseases;3/15/2010, Vol. 50 Issue 6, p833 

    Background. Drug-induced hepatotoxicity (DIH) is the most common adverse drug reaction leading to interruption of antituberculosis treatment. Worldwide, different reintroduction regimens have been advocated, but no consensus guidelines are available. Reintroduction of antituberculosis drugs in...

  • On PPD sensitivity. M.O.R. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p84 

    Responds to a question on whether a positive reaction to purified protein derivative (PPD) can turn PPD-negative after isoniazid (INH) prophylaxis. Notion that most people with tuberculosis infection will remain PPD-positive for life regardless of treatment.

  • Treatment of LTBI -- Is INH It?  // Infectious Disease Alert;Feb2009, Vol. 28 Issue 5, p23 

    The article discusses the comparison between the drugs isoniazid (INH) and rifampin in terms of safety and effectiveness when used as treatment for latent tuberculosis infection (LTBI). It references a study by M. Menzies et al, published in the 2008 issue of the "Annals of Internal Medicine."...

  • Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana. Chideya, Sekai; Winston, Carla A.; Peloquin, Charles A.; Bradford, William Z.; Hopewell, Philip C.; Wells, Charles D.; Reingold, Arthur L.; Kenyon, Thomas A.; Moeti, Themba L.; Tappero, Jordan W. // Clinical Infectious Diseases;6/15/2009, Vol. 48 Issue 12, p1685 

    Background. We explored the association between antituberculosis drug pharmacokinetics and treatment outcomes among patients with pulmonary tuberculosis in Botswana. Methods. Consenting outpatients with tuberculosis had blood samples collected 1, 2, and 6 h after simultaneous isoniazid,...

  • Rifapentine for the Treatment of Pulmonary Tuberculosis. Munsiff, Sonal S.; Kambili, Chrispin; Ahuja, Shama Desai // Clinical Infectious Diseases;12/1/2006, Vol. 43 Issue 11, p1468 

    Rifapentine is a recently approved antituberculosis drug that has not yet been widely used in clinical settings. Clinical data support intermittent use of rifapentine with isoniazid during the continuation phase of tuberculosis treatment. Patients with culture-positive, noncavitary, pulmonary...

  • The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized Study. Spyridis, Nikos P.; Spyridis, Panayotis G.; Gelesme, Anna; Sypsa, Vana; Valianatou, Mina; Metsou, Flora; Gourgiotis, Dimitris; Tsolia, Maria N. // Clinical Infectious Diseases;9/15/2007, Vol. 45 Issue 6, p715 

    Background. A 9-month course of isoniazid monotherapy is currently recommended for the treatment of latent tuberculosis infection (LTBI) and has been shown to be effective in both children and adults. Reduced compliance with this regimen has forced physicians to explore shorter regimens. The aim...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics